medigraphic.com
Anales de Otorrinolaringología Mexicana

2020, Number 4

<< Back

Otorrinolaringología 2020; 65 (4)

Integral management of Meige’s syndrome

Valadez-Jiménez VM, Rodríguez-Mauricio AF, Santamaría-Molina SJ, García-Arango AV

Language: Spanish
References: 31
Page: 221-233
PDF size: 420.06 Kb.


ABSTRACT

Background: Meige’s syndrome is a type of cranial focal dystonia characterized by blepharospasm and oromandibular dystonia, which is associated with complex movements of the lower muscles of the face, mouth, jaw, tongue, pharynx and neck. It is of unknown cause, but with a close relationship between a genetic predisposition and environmental triggers. The treatment options are divided into four groups: oral medications, botulinum toxin, rehabilitation and others advanced procedures, such as deep brain stimulation and denervation surgery in refractory cases.
Clinical case: A 66-year-old female patient with oromandibular, pharyngeal and laryngeal dystonia with blepharospasm, dysphonia, dyspnea and dysphagia, treated with voice therapy, speech and swallowing and botulinum toxin with good results.
Conclusions: In the reported case, the importance of the clinical and instrumented study and the speech therapy that includes pharmacological, rehabilitative intervention, change of habits and safe swallowing measures becomes evident.


REFERENCES

  1. Almedra R, Velon AG, Veiga A, Silva MR. Blepharospasm and Meige syndrome: are there any differences? Toxicon 2015; 93: S2-S67. doi: 10.1016/j.toxicon.2014.11.007

  2. Ananth J, Edelmuth E, Dargan B. Meige’s syndrome associated with neuroleptic treatment. Am J Psychiatry 1988; 145 (4): 513-5. doi: 10.1176/ajp.145.4.513

  3. Tolosa E, Martí MJ. Blepharospasm-oromandibular dystonia syndrome (Meige’s syndrome): clinical aspects. Adv Neurol 1988; 49: 73-84.

  4. Defazio G, Hallet M, Jinnah HA, Conte A, Berardelli A. Blepharospasm 40 years later. Mov Disord 2017; 32 (4): 498-509. doi: 10.1002/mds.26934

  5. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurol 2008; 71 (16): 1275-82. doi: 10.1212/01. wnl.0000327601.46315.85

  6. Valls-Sole J, Defazio G. Blepharospasm: Update on epidemiology, clinical aspects, and pathophysiology. Front Neurol 2016; 7: 45. doi: 10.3389/fneur.2016.00045

  7. Lee JM, Baek JS, Choi HS, Kim SJ, Jang JW. Clinical features of benign essential blepharospasm in Korean patients. Korean J Ophthalmol 2018; 32 (5): 339-343. doi: 10.3341/ kjo.2018.0038

  8. Jahngir MU, Patel BC. Meige syndrome. StatPearls [Internet] 2019. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK513358/

  9. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: Clinical and pharmacological findings in 100 patients. Ann Neurol 1983; 13 (4): 402-411. doi: 10.1002/ ana.410130406

  10. Titi-Lartey O, Patel BC. Benign essential blepharospasm. StatPearls [Internet]. 2020. Disponible en: https://www. ncbi.nlm.nih.gov/books/NBK560833/

  11. LeDoux MS. Meige syndrome: What’s in a name? Parkinsonism Relat Disord 2009; 15 (7): 483-9. doi: 10.1016/j. parkreldis.2009.04.006

  12. Cersósimo MG, Juri S, Suárez de Chandler S, Clerici R, Micheli FE. Swallowing disorders in patients with blepharospasm. Medicina (B Aires) 2005; 65 (2): 117-20.

  13. Verheyden J, Blitzer A. Laryngeal dystonia. Dystonia: etiology, clinical features, and treatment. Philadelphia: Lippincott Williams and Wilkins; 2004; 175-83.10.

  14. Kakigi R, Shibasaki H, Kuroda Y, Shin T, Maeyama T, Oono S. Meige’s syndrome associated with spasmodic dysphagia. J Neurol Neurosurg Psychiatry 1983; 46 (6): 589-90. doi: 10.1136/jnnp.46.6.589

  15. Hwang, CJ, Eftekhari K. Benign essential blepharospasm. Internat Ophthalmol Clin 2018; 58 (1): 11-24. doi:10.1097/ iio.0000000000000207

  16. Pedrero-Escalas MF, García-López I, Santiago-Pérez S, Vivancos F, Gavilán J. Clinical experience with patients with spasmodic dysphonia and primary Meige syndrome. Acta Otorrinolaringol Esp 2019; 70 (1):1-5. doi: 10.1016/j. otorri.2017.11.007

  17. Aramideh M, Bour LJ, Koelman JH, Speelman JD, Ongerboer de Visser BW. Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition. Clinical and pathophysiological considerations. Brain 1994; 117 (Pt 6): 1457-74. doi: 10.1093/brain/117.6.1457

  18. Cobeta I, Núñez F, Fernández S. Patología de la voz. 1ª ed. Barcelona, España. Marge Médica Books, 2013.

  19. Khooshnoodi MA, Factor SA, Jinnah HA. Secondary blepharospasm associated with structural lesions of the brain. J Neurol Sci 2013; 331: 98-101. doi: 10.1016/j. jns.2013.05.022

  20. Horovitz SG, Ford A, Najee-Ullah MA, Ostuni JL, Hallett M. Anatomical correlates of blepharospasm. Transl Neurodegener 2012; 1: 12. doi: 10.1186/2047-9158-1-12

  21. Kerrison JB, Lancaster JL, Zamarripa FE, Richardson LA, Morrison JC, Holck DE. Positron emission tomography scanning in essential blepharospasm. Am J Ophthalmol 2003; 136: 846-52. doi:10.1016/S0002-9394(03)00895-X

  22. Smith EE. Leukoaraiosis and stroke. Stroke 2010; 41 (10 Suppl): S139-43. doi: 10.1161/STROKEAHA.110.596056

  23. Chan LK, Ho HY, Yu CS. Dementia with Lewy bodies in Meige syndrome. Innov Clin Neurosci 2012; 9 (7-8): 39-41.

  24. Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin 2015; 33: 77-100. doi: 10.1016/j. ncl.2014.09.002

  25. Markaki E, Kefalopoulou Z, Georgiopoulos M, Paschali A, Constantoyannis C. Meige’s syndrome: A cranial dystonia treated with bilateral pallidal deep brain stimulation. Clin Neurol Neurosurg 2010; 112 (4): 344-6. doi: 10.1016/j. clineuro.2009.12.005

  26. Houser M, Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov Disord 2005; 20 (9): 1203-5. doi: 10.1002/mds.20522

  27. Sabesan T. Meige syndrome: a rare form of cranial dystonia that was treated successfully with botulinum toxin. Br J Oral Maxillofac Surg 2008; 46 (7): 588-90. doi: 10.1016/j. bjoms.2008.02.002

  28. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin. Experiment Ophthalmol 2014; 42 (3): 254-61.

  29. Kwek ABE, Tan EK, Luman W. Dysphagia as a side effect of botulinum toxin injection. Med J Malaysia 2004; 59 (4): 544-6.

  30. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 1996; 41 (1): 51-65. doi: 10.1016/s0039-6257(97)81995-9

  31. Borodic GE, Ferrante R, Pearce B, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994; 88 (9): 31-39. doi: 10.1002/mds.870090106




2020     |     www.medigraphic.com